Kailera Therapeutics is an advanced clinical-stage biotechnology company focused on developing a diversified pipeline of GLP-1 therapies for obesity treatment. Headquartered in Waltham, Massachusetts, the company advances multiple clinical programs including ribupatide, its lead product candidate that functions as a once-weekly injectable GLP-1/GIP receptor dual agonist peptide currently in global Phase 3 trials. The company also develops oral and injectable formulations targeting various stages of obesity treatment, including KAI-7535, an oral small-molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera holds exclusive worldwide rights outside of China, Hong Kong, Macau, and Taiwan for its therapeutic candidates licensed from Jiangsu Hengrui Pharmaceuticals. The company recently completed its initial public offering and operates within the healthcare biotechnology sector, addressing obesity as a chronic progressive disease affecting over one billion people globally.